Attached files

file filename
8-K - 8-K - IMAX CORPimax-8k_20201029.htm

Exhibit 99.1

 

IMAX CORPORATION REPORTS THIRD QUARTER 2020 RESULTS

HIGHLIGHTS

Global theatrical industry continues opening with IMAX network in Asia almost fully operational and robust local language titles driving IMAX box office grosses near pre-pandemic levels

IMAX ended the quarter with $305 million of cash and cash equivalents

Company expects average monthly cash flow for fourth quarter of 2020 and first quarter of 2021 to be approximately break-even, representing continued free cash flow improvement

IMAX installed 23 systems and signed agreements for ten systems in the quarter, demonstrating continued partner demand for IMAX® theater systems despite the temporary delay of major theatrical releases

As a result of the global pandemic, third quarter 2020 revenue was $37.3 million versus $86.4 million in the third quarter of 2019. Third quarter 2020 net (loss) attributable to common shareholders was ($47.2) million versus $9.0 million in the prior-year period. Third quarter financial results include the following non-cash items: $23.7 million or $0.40 per share deferred tax asset valuation allowance, $5.7 million film asset impairment, and a $3.9 million provision for credit losses

Non-GAAP adjusted EBITDA (loss) was ($0.3) million in third quarter 2020 versus $32.4 million in the prior-year period

 

 

Three Months Ended

 

 

 

September 30,

 

In thousands except per share data

 

2020

 

 

2019

 

 

YoY %

Change

 

Total Revenue

 

$

37.3

 

 

$

86.4

 

 

 

(56.9

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Margin

 

$

3.8

 

 

$

47.1

 

 

 

(91.9

%)

Gross Margin (%)

 

 

10.3

%

 

 

54.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (Loss) Income attributable to common shareholders

 

$

(47.2

)

 

$

9.0

 

 

N/A

 

Diluted Net (Loss) Income per share attributable to common shareholders

 

$

(0.80

)

 

$

0.15

 

 

N/A

 

Adjusted Net (Loss) Income attributable to common shareholders(1)

 

$

(44.6

)

 

$

12.8

 

 

N/A

 

Adjusted Net (Loss) Income per share attributable to common shareholders(1)

 

$

(0.75

)

 

$

0.21

 

 

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA per Credit Facility attributable to common shareholders(1)

 

$

(0.3

)

 

$

32.4

 

 

N/A

 

Adjusted EBITDA Margin attributable to common shareholders (%) (1)

 

 

(0.8

%)

 

 

41.4

%

 

N/A

 

_____________

(1)

Non-GAAP Financial Measure

 

Note: For the definition and reconciliations of reported results to non-GAAP financial results, please refer to the discussion of non-GAAP financial measures at the end of this earnings release.


1


NEW YORK – October 29, 2020 – IMAX Corporation (NYSE:IMAX) today reported third quarter results as the global theatrical industry continues recovery, highlighted by a notably resurgent box office in Asia. IMAX reported improved cash flow and further reduced costs while benefiting from the Company’s diversified global footprint, continued growth in its theater network as well as the robust Asian film market - particularly in China and Japan - where audiences are returning to theaters attracted by a strong local language slate.

As the only global theatrical platform for blockbuster entertainment, our experience around the world has proven that audiences will enthusiastically return to the movies where theaters are open and they feel safe. As they do return, they are coming back to IMAX — underscoring the enduring strength of our brand and the power of The IMAX Experience®,” said IMAX CEO, Richard L. Gelfond.

“With continued box office revenues from our strong local language slate and revenues from theater installations, the Company estimates our average monthly cash flow will be approximately break-even through the first quarter of 2021.”

“Our multi-year strategic effort to geographically diversify our business is paying off, as our strong local language slate continues to partially offset the lack of Hollywood releases in the market. From the year’s number-one global box office release in China, “The Eight Hundred” — the first commercial Asian film shot entirely with IMAX cameras — to Japan’s record-breaking “Demon Slayer”, we believe that IMAX is poised to benefit from the impressive resurgence of the Asian film market. IMAX has no fewer than 10 local language releases in the fourth quarter of 2020, with the promising Chinese New Year box office period on its heels in February.”

“IMAX remains well-positioned to manage through the continued recovery of the global film industry as cinemas await the return of Hollywood tentpoles. We have a significant financial runway with $305 million of cash on our balance sheet at the end of the third quarter.”

The Company reported 2020 revenues of $37.3 million, gross margin of $3.8 million, and a net (loss) attributable to common shareholders of ($47.2) million, or ($0.80) per diluted share.

IMAX results reflect the COVID-19 related closure of the majority of the Company’s network through a portion of the third quarter. Third quarter financial results also reflect the inclusion of a number of notable non-cash items related to COVID-19 driven uncertainty, the delay of Hollywood releases, and the reclosure of theaters in some markets. These non-cash items include: a $23.7 million valuation allowance to reduce the value of deferred tax assets; a $5.7 million impairment loss related to documentary and alternative content films assets; and a $3.9 million provision for current expected credit losses reflecting a reduction in the credit quality of the theater receivable balances.  

Third Quarter and September Year-to-Date Segment Results(1)

 

 

 

IMAX Technology Network

 

 

IMAX Technology Sales and Maintenance

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

Gross Margin

(Margin Loss)

 

 

Gross Margin

(Margin Loss) %

 

 

Revenue

 

 

Gross Margin

 

 

Gross Margin %

 

3Q20

 

$

11.4

 

 

$

0.6

 

 

 

5.2

%

 

$

23.7

 

 

 

$

9.4

 

 

 

39.6

%

3Q19

 

43.3

 

 

 

27.4

 

 

 

63.3

%

 

37.6

 

 

 

 

18.4

 

 

 

48.9

%

% change

 

 

(73.7

%)

 

 

(97.9

%)

 

 

 

 

 

 

(37.1

%)

 

 

 

(49.1

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

YTD 3Q20

 

$

28.4

 

 

$

(3.1

)

 

 

(11.0

%)

 

$

43.4

 

 

 

$

14.3

 

 

 

33.0

%

YTD 3Q19

 

154.1

 

 

 

102.4

 

 

 

66.4

%

 

 

102.6

 

 

 

 

46.9

 

 

 

45.7

%

% change

 

 

(81.6

%)

 

 

(103.0

%)

 

 

 

 

 

 

(57.7

%)

 

 

 

(69.4

%)

 

 

 

 

_____________

(1) Please refer to the Company’s Form 10-Q for the period ended September 30, 2020 for additional segment information

2


 

IMAX Technology Network

 

IMAX Technology Network revenues decreased 73.7% to $11.4 million in the third quarter of 2020, compared to $43.3 million in the prior-year period. The closure of the Company’s network through the first half of the quarter, the partial opening of theaters in late August and September, and the release of fewer films as Hollywood continues to delay major titles impacted year over year results.

 

Gross margin for the IMAX Technology Network was $0.6 million in the third quarter of 2020 and was driven by lower revenue and ongoing fixed costs associated with our installed IMAX network.

IMAX Technology Sales and Maintenance

 

IMAX Technology Sales and Maintenance revenues decreased 37.1% to $23.7 million in the third quarter of 2020, compared with $37.6 million in the prior year period. Five fewer sales and sales type lease installations resulted in lower IMAX system revenue. IMAX maintenance revenue declined to $5.9 million as COVID-19-related closures of IMAX theater systems through a portion of the quarter prevented the recognition of revenue.

 

Total gross margin for IMAX Technology Sales and Maintenance was $9.4 million compared to $18.4 million in the prior year period.

 

Cash Balances and Outstanding Debt

Total cash and cash equivalents as of September 30, 2020 were $305 million. Total debt, excluding deferred financing fees, was $300.3 million as of September 30, 2020.

 

Share Count and Capital Return

The weighted average diluted shares outstanding at the end of the third quarter of 2020 declined 4.3% to 58.9 million, compared to 61.5 million in the third quarter of 2019, due primarily to share repurchase activity during the twelve-month period. During the third quarter of 2020, the Company did not repurchase any stock. A total of $89.4 million remains available under the Company’s outstanding share repurchase authorization, which was extended in June 2020 and now expires in June 2021.

Supplemental Materials

For more information about the Company’s results, please refer to the IMAX Investor Relations website located at investors.imax.com.

 

Investor Relations Website and Social Media

On a weekly basis, the Company posts quarter-to-date box office results on the IMAX Investor Relations website located at investors.imax.com. The Company expects to provide such updates on Friday of each week, although the Company may change this timing without notice. Results will be displayed with a one-week lag.

 

The information posted on the Company’s corporate and Investor Relations website may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company’s website in addition to the Company’s press releases, SEC filings and public conference calls and webcasts.

 


3


Conference Call

The Company will host a conference call today at 8:30AM ET to discuss its third quarter 2020 financial results. This call is being webcast by PGI and can be accessed at investors.imax.com. To access the call via telephone, interested parties in the US and Canada should dial (800) 367-2403 approximately 5 to 10 minutes before the call begins. Other international callers should dial (647) 490-5367. The conference ID for the call is 4692103. A replay of the call will be available via webcast at investors.imax.com or via telephone by dialing (888) 203-1112 (US and Canada), or (647) 436-0148 (international). The Conference ID for the telephone replay is 4692103.

 

About IMAX Corporation

IMAX, an innovator in entertainment technology, combines proprietary software, architecture and equipment to create experiences that take you beyond the edge of your seat to a world you’ve never imagined. Top filmmakers and studios are utilizing IMAX theaters to connect with audiences in extraordinary ways, and, as such, IMAX’s network is among the most important and successful theatrical distribution platforms for major event films around the globe.

 

IMAX is headquartered in New York, Toronto, and Los Angeles, with additional offices in London, Dublin, Tokyo, and Shanghai. As of September 30, 2020, there were 1,632 IMAX theater systems (1,542 commercial multiplexes, 13 commercial destinations, 77 institutional) operating in 82 countries and territories. Shares of IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trade on the Hong Kong Stock Exchange under the stock code “HK.1970.”

 

IMAX®, IMAX® Dome, IMAX® 3D, IMAX® 3D Dome, Experience It In IMAX®, The IMAX Experience®, An IMAX Experience®, An IMAX 3D Experience®, IMAX DMR®, DMR®, IMAX nXos® and Films to the Fullest®, are trademarks and trade names of the Company or its subsidiaries that are registered or otherwise protected under laws of various jurisdictions. More information about the Company can be found at www.imax.com. You may also connect with IMAX on Instagram (https://www.instagram.com/imax), Facebook (www.facebook.com/imax), Twitter (www.twitter.com/imax) and YouTube (www.youtube.com/imaxmovies).

 

For additional information please contact:

 

Investors:

IMAX Corporation, New York

Brett Harriss

212-821-0187

bharriss@IMAX.com

 

 

Media:

IMAX Corporation, New York

Mark Jafar

212-821-0102

mjafar@imax.com

 

 

 

###

4


Forward-Looking Statements

 

This earnings release contains forward looking statements that are based on IMAX management's assumptions and existing information and involve certain risks and uncertainties which could cause actual results to differ materially from future results expressed or implied by such forward looking statements. Important factors that could affect these statements include, but are not limited to, references to business and technology strategies and measures to implement strategies, competitive strengths, goals, expansion and growth of business, operations and technology, future capital expenditures (including the amount and nature thereof), plans and references to the future success of IMAX Corporation together with its consolidated subsidiaries (the "Company") and expectations regarding the Company's future operating, financial and technological results. These forward-looking statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. However, whether actual results and developments will conform with the expectations and predictions of the Company is subject to a number of risks and uncertainties, including, but not limited to, risks associated with investments and operations in foreign jurisdictions and any future international expansion, including those related to economic, political and regulatory policies of local governments and laws and policies of the United States and Canada; risks related to the Company’s growth and operations in China; the performance of IMAX DMR® films; the signing of IMAX Theater System agreements; conditions, changes and developments in the commercial exhibition industry; risks related to currency fluctuations; the potential impact of increased competition in the markets within which the Company operates; competitive actions by other companies; the failure to respond to change and advancements in digital technology; risks relating to recent consolidation among commercial exhibitors and movie studios; risks related to new business initiatives; conditions in the in-home and out-of-home entertainment industries; the opportunities (or lack thereof) that may be presented to and pursued by the Company; risks related to cyber-security and data privacy; risks related to the Company’s inability to protect the Company’s intellectual property; general economic, market or business conditions; the failure to convert IMAX Theater System backlog into revenue; changes in laws or regulations; the failure to fully realize the projected cost savings and benefits from any of the Company’s restructuring initiatives; the impact of COVID-19 on our financial condition and results of operations and on the businesses of our customers and exhibitor partners; and other factors, many of which are beyond the control of the Company. Consequently, all of the forward-looking statements made in this earnings release are qualified by these cautionary statements, and actual results or anticipated developments by the Company may not be realized, and even if substantially realized, may not have the expected consequences to, or effects on, the Company. These factors, other risks and uncertainties and financial details are discussed in IMAX’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

Primary Reporting Groups

The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-production. The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided:

 

 

(i)

IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangement (“JRSA”) segment;

 

5


 

(ii)

IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment;

 

 

(iii)

New Business Initiatives, which is a segment that includes activities related to the exploration of new lines of business and new initiatives outside of the Company’s core business; and

 

 

(iv)

Film Distribution and Post-production, which includes activities related to the licensing of film content, the distribution of films primarily for the Company’s institutional theater partners (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-production segment).

 

 

 

6


Signings and Installations

 

 

 

Three Months

Ended September 30,

 

 

Theater System Signings:

 

2020

 

 

 

2019

 

 

Full new sales and sales-type lease arrangements

 

 

8

 

 

 

 

22

 

 

New hybrid joint revenue sharing lease arrangements

 

 

-

 

 

 

 

-

 

 

New traditional joint revenue sharing arrangements

 

 

-

 

 

 

 

-

 

 

Total new IMAX theaters

 

 

8

 

 

 

 

22

 

 

Upgrades of IMAX theater systems

 

 

2

 

 

 

 

8

 

 

Total theater signings

 

 

10

 

 

 

 

30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Ended September 30,

 

 

Theater System Installations:

 

2020

 

 

 

2019

 

 

Full new sales and sales-type lease arrangements

 

 

9

 

 

 

 

14

 

 

New hybrid joint revenue sharing lease arrangements

 

 

1

 

 

 

 

4

 

 

New traditional joint revenue sharing arrangements

 

 

8

 

 

 

 

12

 

 

Total new IMAX theaters

 

 

18

 

 

 

 

30

 

 

Upgrades of IMAX theater systems

 

 

5

 

 

 

 

9

 

 

Total theater installations

 

 

23

 

 

 

 

39

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Ended September 30,

 

 

Theater Sales Backlog:

 

2020

 

 

 

2019

 

 

Sales and sales-type lease arrangements

 

 

193

 

 

 

 

205

 

 

Hybrid JRSA

 

 

146

 

 

 

 

149

 

 

Traditional JRSA

 

 

206

 

(1)

 

 

253

 

(1)

Total theater backlog

 

 

545

 

(2)

 

 

607

 

(3)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Ended September 30,

 

 

Theater Network:

 

2020

 

 

 

2019

 

 

Commercial Multiplex Theaters:

 

 

 

 

 

 

 

 

 

 

Sales and sales-type lease arrangements

 

 

661

 

 

 

 

632

 

 

Hybrid joint revenue sharing lease arrangements

 

 

139

 

 

 

 

135

 

 

Traditional joint revenue sharing lease arrangements

 

 

742

 

 

 

 

706

 

 

Total Commercial Multiplex Theaters(4)

 

 

1,542

 

 

 

 

1,473

 

 

Commercial Destination Theaters

 

 

13

 

 

 

 

14

 

 

Institutional Theaters

 

 

77

 

 

 

 

81

 

 

Total theater network

 

 

1,632

 

 

 

 

1,568

 

 

_____________

(1)   Includes 46 IMAX Theater Systems where the customer has the option to convert from a joint revenue sharing arrangement to a sales arrangement (2019 — 50).

(2) Includes 155 new IMAX with Laser projection system configurations and 92 upgrades of existing locations to IMAX with Laser projection system configurations.

(3) Includes 145 new IMAX with Laser projection system configurations and 119 upgrades of existing locations to IMAX with Laser projection system configurations.

(4)   Period to period changes are net of the effects of permanently closed theaters.         

7


IMAX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

 

September 30,

 

 

September 30,

 

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Technology sales

 

$

15,753

 

 

$

21,735

 

 

$

24,102

 

 

$

56,629

 

Image enhancement and maintenance services

 

 

14,589

 

 

 

44,168

 

 

 

39,109

 

 

 

144,977

 

Technology rentals

 

 

4,473

 

 

 

17,642

 

 

 

10,307

 

 

 

61,675

 

Finance income

 

 

2,441

 

 

 

2,845

 

 

 

7,495

 

 

 

8,104

 

 

 

 

 

37,256

 

 

 

86,390

 

 

 

81,013

 

 

 

271,385

 

Costs and expenses applicable to revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Technology sales

 

 

9,222

 

 

 

11,740

 

 

 

15,637

 

 

 

33,114

 

Image enhancement and maintenance services

 

 

16,989

 

 

 

20,181

 

 

 

42,049

 

 

 

66,205

 

Technology rentals

 

 

7,216

 

 

 

7,349

 

 

 

22,100

 

 

 

20,253

 

 

 

 

 

33,427

 

 

 

39,270

 

 

 

79,786

 

 

 

119,572

 

Gross margin

 

 

3,829

 

 

 

47,120

 

 

 

1,227

 

 

 

151,813

 

Selling, general and administrative expenses

 

 

24,815

 

 

 

29,482

 

 

 

83,247

 

 

 

89,267

 

Research and development

 

 

1,130

 

 

 

1,359

 

 

 

4,562

 

 

 

3,717

 

Amortization of intangibles

 

 

1,349

 

 

 

1,271

 

 

 

4,014

 

 

 

3,564

 

Credit loss expense

 

 

3,925

 

 

 

599

 

 

 

15,582

 

 

 

1,957

 

Asset impairments

 

 

-

 

 

 

-

 

 

 

1,151

 

 

 

-

 

Exit costs, restructuring charges and associated impairments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

850

 

(Loss) income from operations

 

 

(27,390

)

 

 

14,409

 

 

 

(107,329

)

 

 

52,458

 

Gain (loss) in fair value of investments

 

 

1,575

 

 

 

(490

)

 

 

(939

)

 

 

(2,543

)

Retirement benefits non-service expense

 

 

(186

)

 

 

(160

)

 

 

(432

)

 

 

(480

)

Interest income

 

 

586

 

 

 

490

 

 

 

1,842

 

 

 

1,632

 

Interest expense

 

 

(2,391

)

 

 

(489

)

 

 

(4,620

)

 

 

(1,806

)

(Loss) income before taxes

 

 

(27,806

)

 

 

13,760

 

 

 

(111,478

)

 

 

49,261

 

Income tax expense

 

 

(19,349

)

 

 

(3,030

)

 

 

(24,606

)

 

 

(11,986

)

Equity in (losses) gains of investees, net of tax

 

(1,329

)

 

 

166

 

 

 

(1,858

)

 

 

(56

)

Net (loss) income

 

 

(48,484

)

 

 

10,896

 

 

 

(137,942

)

 

 

37,219

 

Less: Net loss (income) attributable to non-controlling interests

 

 

1,275

 

 

 

(1,863

)

 

 

15,412

 

 

 

(8,524

)

Net (loss) income attributable to common shareholders

 

$

(47,209

)

 

$

9,033

 

 

$

(122,530

)

 

$

28,695

 

Net (loss) income per share attributable to common shareholders -

      basic and diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share — basic and diluted

 

$

(0.80

)

 

$

0.15

 

 

$

(2.06

)

 

$

0.47

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding (000's):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

58,859

 

 

 

61,304

 

 

 

59,360

 

 

 

61,337

 

 

Fully Diluted

 

 

58,859

 

 

 

61,479

 

 

 

59,360

 

 

 

61,509

 

Additional Disclosure:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization(1)

 

$

14,112

 

 

$

15,696

 

 

$

41,294

 

 

$

45,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Includes $0.3 million and $0.6 million of amortization of deferred financing costs charged to interest expense for the three months and nine months ended September 30, 2020, respectively ($0.1 million and $0.4 million, respectively).

 

 

 

8


IMAX CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

In accordance with United States Generally Accepted Accounting Principles

(In thousands of dollars, except share amounts)

(Unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

305,197

 

 

$

109,484

 

Accounts receivable, net of allowance for credit losses

 

 

59,674

 

 

 

99,513

 

Financing receivables, net of allowance for credit losses

 

 

126,740

 

 

 

128,038

 

Variable consideration receivable, net of allowance for credit losses

 

 

39,394

 

 

 

40,040

 

Inventories

 

 

53,021

 

 

 

42,989

 

Prepaid expenses

 

 

10,812

 

 

 

10,237

 

Film assets

 

 

7,468

 

 

 

17,921

 

Property, plant and equipment

 

 

282,854

 

 

 

306,849

 

Investment in equity securities

 

 

14,803

 

 

 

15,685

 

Other assets

 

 

23,796

 

 

 

25,034

 

Deferred income tax assets

 

 

17,737

 

 

 

23,905

 

Other intangible assets

 

 

27,019

 

 

 

30,347

 

Goodwill

 

 

39,027

 

 

 

39,027

 

Total assets

 

$

1,007,542

 

 

$

889,069

 

Liabilities

 

 

 

 

 

 

 

 

Bank indebtedness

 

$

297,985

 

 

$

18,229

 

Accounts payable

 

 

12,011

 

 

 

20,414

 

Accrued and other liabilities

 

 

103,970

 

 

 

112,779

 

Deferred revenue

 

 

99,770

 

 

 

94,552

 

Deferred income tax liabilities

 

 

18,661

 

 

 

 

Total liabilities

 

 

532,397

 

 

 

245,974

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Non-controlling interests

 

 

776

 

 

 

5,908

 

Shareholders' equity

 

 

 

 

 

 

 

 

Capital stock common shares — no par value. Authorized — unlimited number.

 

 

 

 

 

 

 

 

58,878,749 issued and 58,861,171 outstanding (December 31, 2019 — 61,362,872 issued and 61,175,852 outstanding)

 

 

405,583

 

 

 

423,386

 

Less: Treasury stock, 17,578 shares at cost (December 31, 2019 — 187,020)

 

 

(271

)

 

 

(4,038

)

Other equity

 

 

177,110

 

 

 

171,789

 

Accumulated deficit

 

 

(181,604

)

 

 

(40,253

)

Accumulated other comprehensive loss

 

 

(1,984

)

 

 

(3,190

)

Total shareholders' equity attributable to common shareholders

 

 

398,834

 

 

 

547,694

 

Non-controlling interests

 

 

75,535

 

 

 

89,493

 

Total shareholders' equity

 

 

474,369

 

 

 

637,187

 

Total liabilities and shareholders' equity

 

$

1,007,542

 

 

$

889,069

 

 

9


IMAX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of dollars)

(Unaudited)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2020

 

 

2019

 

Cash (used in) provided by:

 

 

 

 

 

 

 

 

Operating Activities

 

 

 

 

 

 

 

 

Net (loss) income

 

$

(137,942

)

 

$

37,219

 

Adjustments to reconcile net (loss) income to cash from operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

41,294

 

 

 

45,500

 

Credit loss expense

 

 

15,582

 

 

 

1,957

 

Write-downs

 

 

13,339

 

 

 

1,027

 

Deferred income tax expense

 

 

23,142

 

 

 

1,035

 

Share-based and other non-cash compensation

 

 

16,345

 

 

 

17,397

 

Unrealized foreign currency exchange (gain) loss

 

 

(394

)

 

 

214

 

Loss in fair value of equity securities

 

 

939

 

 

 

2,543

 

Equity in losses of investees

 

 

1,858

 

 

 

56

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

30,350

 

 

 

9,613

 

Inventories

 

 

(10,278

)

 

 

(13,422

)

Film Assets

 

 

(6,177

)

 

 

(15,405

)

Deferred revenue

 

 

5,233

 

 

 

(2,599

)

Changes in other operating assets and liabilities

 

 

(24,109

)

 

 

(17,878

)

Net cash (used in) provided by operating activities

 

 

(30,818

)

 

 

67,257

 

Investing Activities

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

(658

)

 

 

(5,528

)

Investment in equipment for joint revenue sharing arrangements

 

 

(5,289

)

 

 

(31,099

)

Acquisition of other intangible assets

 

 

(1,661

)

 

 

(1,874

)

Investment in equity securities

 

 

 

 

 

(15,153

)

Net cash used in investing activities

 

 

(7,608

)

 

 

(53,654

)

Financing Activities

 

 

 

 

 

 

 

 

Increase in revolving credit facility borrowings

 

 

280,244

 

 

 

35,000

 

Repayment of revolving credit facility borrowings

 

 

 

 

 

(55,000

)

Credit facility amendment fees paid

 

 

(1,026

)

 

 

 

Settlement of restricted share units and options

 

 

(2,815

)

 

 

(8,589

)

Treasury stock repurchased for future settlement of restricted share units

 

 

(271

)

 

 

(1,572

)

Repurchase of common shares, IMAX China

 

 

(1,534

)

 

 

(19,157

)

Taxes withheld and paid on employee stock awards vested

 

 

(251

)

 

 

(508

)

Common shares issued - stock options exercised

 

 

 

 

 

2,391

 

Repurchase of common shares

 

 

(36,624

)

 

 

(2,659

)

Issuance of subsidiary shares to non-controlling interests (net of return on capital)

 

 

 

 

 

1,106

 

Dividends paid to non-controlling interests

 

 

(4,214

)

 

 

(4,384

)

Net cash provided by (used in) financing activities

 

 

233,509

 

 

 

(53,372

)

Effects of exchange rate changes on cash

 

 

630

 

 

 

727

 

Increase (decrease) in cash and cash equivalents during period

 

 

195,713

 

 

 

(39,042

)

Cash and cash equivalents, beginning of period

 

 

109,484

 

 

 

141,590

 

Cash and cash equivalents, end of period

 

$

305,197

 

 

$

102,548

 

10


 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMAX Technology Network

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMAX DMR

 

$

6,886

 

 

$

26,665

 

 

$

18,061

 

 

$

93,908

 

Joint revenue sharing arrangements, contingent rent

 

 

4,473

 

 

 

16,605

 

 

 

10,307

 

 

 

60,189

 

 

 

 

11,359

 

 

 

43,270

 

 

 

28,368

 

 

 

154,097

 

IMAX Technology Sales and Maintenance

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMAX Systems

 

 

17,437

 

 

 

20,977

 

 

 

27,674

 

 

 

50,504

 

Joint revenue sharing arrangements, fixed fees

 

 

57

 

 

 

1,438

 

 

 

1,196

 

 

 

6,525

 

IMAX Maintenance

 

 

5,855

 

 

 

13,657

 

 

 

13,225

 

 

 

39,815

 

Other Theater Business

 

 

307

 

 

 

1,560

 

 

 

1,261

 

 

 

5,766

 

 

 

 

23,656

 

 

 

37,632

 

 

 

43,356

 

 

 

102,610

 

New Business Initiatives

 

 

378

 

 

 

596

 

 

 

1,488

 

 

 

1,908

 

Film Distribution and Post-production

 

 

1,865

 

 

 

3,528

 

 

 

7,541

 

 

 

9,791

 

 

 

 

37,258

 

 

 

85,026

 

 

 

80,753

 

 

 

268,406

 

Other

 

 

(2

)

 

 

1,364

 

 

 

260

 

 

 

2,979

 

Total revenues

 

$

37,256

 

 

$

86,390

 

 

$

81,013

 

 

$

271,385

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Margin (Margin Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMAX Technology Network

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMAX DMR(1)

 

$

3,079

 

 

$

17,866

 

 

$

7,492

 

 

$

61,602

 

Joint revenue sharing arrangements, contingent rent(1)

 

 

(2,491

)

 

 

9,524

 

 

 

(10,610

)

 

 

40,777

 

 

 

 

588

 

 

 

27,390

 

 

 

(3,118

)

 

 

102,379

 

IMAX Technology Sales and Maintenance

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMAX Systems (1)

 

 

8,671

 

 

 

11,652

 

 

 

14,497

 

 

 

26,723

 

Joint revenue sharing arrangements, fixed fees(1)

 

 

(117

)

 

 

136

 

 

 

110

 

 

 

1,301

 

IMAX Maintenance

 

 

794

 

 

 

6,125

 

 

 

(355

)

 

 

17,046

 

Other Theater Business

 

 

31

 

 

 

505

 

 

 

77

 

 

 

1,821

 

 

 

 

9,379

 

 

 

18,418

 

 

 

14,329

 

 

 

46,891

 

New Business Initiatives

 

 

372

 

 

 

541

 

 

 

1,245

 

 

 

1,441

 

Film Distribution and Post-production (1)(2)

 

 

(6,061

)

 

 

50

 

 

 

(9,392

)

 

 

483

 

 

 

 

4,278

 

 

 

46,399

 

 

 

3,064

 

 

 

151,194

 

Other

 

 

(449

)

 

 

721

 

 

 

(1,837

)

 

 

619

 

Total Segment Margin

 

$

3,829

 

 

$

47,120

 

 

$

1,227

 

 

$

151,813

 

__________________

(1)   IMAX DMR gross margin includes marketing expense of $0.4 million and $2.8 million for the three and nine months ended September 30, 2020, respectively (2019 — $4.3 million and $17.7 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of $0.7 million and $1.3 million for the three and nine months ended September 30, 2020, respectively (2019 —$0.8 million and $1.1 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.6 million and $1.0 million for the three and nine months ended September 30, 2020, respectively, (2019 — $0.6 million and $1.5 million, respectively). Film Distribution segment gross margin includes marketing expense of $0.2 million and $0.4 million for the three and nine months ended September 30, 2020, respectively (2019 — $0.1 million and $0.7 million, respectively).

(2)  Film Distribution margins were significantly influenced by impairment loss recorded of $5.4 million and $9.9 million for the three and nine months ended September 30, 2020 to write-down the carrying value of certain documentary and alternative content film assets (2019 – $0.2 million and $0.2 million).

 

 

 

 

 

 

 

 

 

 

11


 

IMAX CORPORATION

OTHER INFORMATION

(in thousands of U.S. dollars)

Non-GAAP Financial Measures:

In this release, the Company presents adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders per diluted share, EBITDA, Adjusted EBITDA per Credit Facility, Adjusted EBITDA margin, and free cash flow as supplemental measures of the Company’s performance, which are not recognized under U.S. GAAP. Adjusted net (loss) income attributable to common shareholders and adjusted net (loss) income attributable to common shareholders per diluted share exclude, where applicable: (i) share-based compensation; (ii) exit costs, restructuring charges and associated impairments, (iii) gain (loss) in the fair value of investments, (iv) COVID-19 government relief benefits, as well as the related tax impact of these adjustments, and (v) the income tax effects related to the removal of the indefinitely reinvested assertion on the historical earnings of certain subsidiaries.

The Company believes that these non-GAAP financial measures are important supplemental measures that allow management and users of the Company’s financial statements to view operating trends and analyze controllable operating performance on a comparable basis between periods without the after-tax impact of share-based compensation and certain unusual items included in net (loss) income attributable to common shareholders. Although share-based compensation is an important aspect of the Company’s employee and executive compensation packages, it is a non-cash expense and is excluded from certain internal business performance measures.

A reconciliation of net (loss) income attributable to common shareholders and the comparable per share amounts, the most directly comparable GAAP measure to adjusted net (loss) income attributable to common shareholders, adjusted net (loss) income attributable to common shareholders per diluted share, EBITDA, Adjusted EBITDA per Credit Facility and Adjusted EBITDA margin is presented in the table below. The Company believes that net (loss) income attributable to common shareholders is the most directly comparable GAAP measure because it reflects the earnings relevant to the Company’s shareholders, rather than including the non-controlling interest. As such, beginning in the first quarter of 2020, the Company has updated the reconciliations for such non-GAAP financial measures included herein.

In addition to the non-GAAP financial measures discussed above, management also uses “EBITDA,” as such term is defined in the Credit Agreement, and which is referred to herein as “Adjusted EBITDA per Credit Facility.” As allowed by the Credit Agreement, Adjusted EBITDA per Credit Facility includes adjustments in addition to the exclusion of interest, taxes, depreciation and amortization. Accordingly, this non-GAAP financial measure is presented to allow a more comprehensive analysis of the Company’s operating performance and to provide additional information with respect to the Company’s compliance against its Credit Agreement requirements in the current period, if applicable. In addition, the Company believes that Adjusted EBITDA per Credit Facility presents relevant and useful information widely used by analysts, investors and other interested parties in the Company’s industry to evaluate, assess and benchmark the Company’s results.

EBITDA is defined as net (loss) income excluding (i) interest expense, net of interest income; (ii) income tax (benefit) expense; and (iii) depreciation and amortization, including film asset amortization. Adjusted EBITDA per Credit Facility is defined as EBITDA excluding: (i) share-based and other non-cash compensation; (ii) gain (loss) in fair value of investments; (iii) write-downs, net of recoveries, including asset impairments and credit loss expense; (iv) gain (loss) from equity accounted investments; (v) exit costs, restructuring charges and associated impairments; (vi) legal arbitration award; and (vii) executive transition costs.

Free cash flow is defined as cash provided by operating activities minus cash used in investing activities (from the condensed consolidated statements of cash flows). Cash provided by operating activities consist of net (loss) income, plus depreciation and amortization, plus the change in deferred income taxes, plus other non-cash items, plus changes in working capital, less investment in film assets, plus other changes in operating assets and liabilities. Cash used in investing activities includes capital expenditures, acquisitions and other cash used in investing activities. Management views free cash flow, a non-GAAP measure, as a measure of the Company’s after-tax cash flow available to reduce debt, add to cash balances, and fund other financing activities. Free cash flow does not represent residual cash flow available for discretionary expenditures. A reconciliation of cash provided by operating activities to free cash flow is presented below.

12


These non-GAAP measures may not be comparable to similarly titled amounts reported by other companies. Additionally, the non-GAAP financial measures used by the Company should not be considered as a substitute for, or superior to, the comparable GAAP amounts. A reconciliation of each of these non-GAAP measures to the most directly comparable GAAP measures is presented below.

 

 

 

For the Three Months Ended September 30, 2020

 

 

For the Three Months Ended September 30, 2019

 

 

 

Attributable to

Non-controlling

 

 

Less:

 

 

 

 

 

Attributable to

Non-controlling

 

 

Less:

 

 

 

 

 

 

Interests and

 

 

Attributable to

 

 

Attributable to

 

 

Interests and

 

 

Attributable to

 

 

Attributable to

 

 

 

Common

 

 

Non-controlling

 

 

Common

 

 

Common

 

 

Non-controlling

 

 

Common

 

 

 

Shareholders

 

 

Interests

 

 

Shareholders

 

 

Shareholders

 

 

Interests

 

 

Shareholders

 

(In thousands of U.S. Dollars)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net loss

 

$

 

(48,484

)

 

$

 

(1,275

)

 

$

 

(47,209

)

 

$

 

10,896

 

 

$

 

1,863

 

 

$

 

9,033

 

Add (subtract):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

 

 

19,349

 

 

 

 

(503

)

 

 

 

19,852

 

 

 

 

3,030

 

 

 

 

654

 

 

 

 

2,376

 

Interest expense, net of interest income

 

 

 

1,509

 

 

 

 

(81

)

 

 

 

1,590

 

 

 

 

(133

)

 

 

 

(117

)

 

 

 

(16

)

Depreciation and amortization, including film asset

   amortization

 

 

 

14,112

 

 

 

 

1,182

 

 

 

 

12,930

 

 

 

 

15,696

 

 

 

 

1,342

 

 

 

 

14,354

 

EBITDA

 

$

 

(13,514

)

 

$

 

(677

)

 

$

 

(12,837

)

 

$

 

29,489

 

 

$

 

3,742

 

 

$

 

25,747

 

Share-based and other non-cash compensation

 

 

 

5,495

 

 

 

 

292

 

 

 

 

5,203

 

 

 

 

5,687

 

 

 

 

137

 

 

 

 

5,550

 

(Gain) loss in fair value of investments

 

 

 

(1,575

)

 

 

 

(484

)

 

 

 

(1,091

)

 

 

 

490

 

 

 

 

156

 

 

 

 

334

 

Write-downs, including asset

impairments and credit loss expense

 

 

 

10,458

 

 

 

 

3,324

 

 

 

 

7,134

 

 

 

 

1,118

 

 

 

 

154

 

 

 

 

964

 

Loss (gain) from equity accounted investments

 

 

 

1,329

 

 

 

 

 

 

 

 

1,329

 

 

 

 

(166

)

 

 

 

 

 

 

 

(166

)

Adjusted EBITDA per Credit Facility

 

$

 

2,193

 

 

$

 

2,455

 

 

$

 

(262

)

 

$

 

36,618

 

 

$

 

4,188

 

 

$

 

32,430

 

Revenues attributable to common

   shareholders(2)

 

 

 

37,256

 

 

 

 

5,825

 

 

 

 

31,431

 

 

 

 

86,390

 

 

 

 

8,036

 

 

 

 

78,354

 

Adjusted EBITDA margin attributable to common

   shareholders

 

 

 

5.9

%

 

 

 

42.1

%

 

 

 

(0.8

%)

 

 

 

42.4

%

 

 

 

52.1

%

 

 

 

41.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Twelve Months Ended September 30, 2020 (1)

 

 

For the Twelve Months Ended September 30, 2019 (1)

 

 

 

Attributable to

Non-controlling

 

 

Less:

 

 

 

 

 

Attributable to

Non-controlling

 

 

Less:

 

 

 

 

 

 

Interests and

 

 

Attributable to

 

 

Attributable to

 

 

Interests and

 

 

Attributable to

 

 

Attributable to

 

 

 

Common

 

 

Non-controlling

 

 

Common

 

 

Common

 

 

Non-controlling

 

 

Common

 

 

 

Shareholders

 

 

Interests

 

 

Shareholders

 

 

Shareholders

 

 

Interests

 

 

Shareholders

 

(In thousands of U.S. Dollars)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported net loss

 

$

 

(116,590

)

 

$

 

(12,231

)

 

$

 

(104,359

)

 

$

 

40,990

 

 

$

 

10,601

 

 

$

 

30,389

 

Add (subtract):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

 

29,388

 

 

 

 

5,549

 

 

 

 

23,839

 

 

 

 

11,964

 

 

 

 

3,581

 

 

 

 

8,383

 

Interest expense, net of interest income

 

 

 

2,564

 

 

 

 

(388

)

 

 

 

2,952

 

 

 

 

(68

)

 

 

 

(224

)

 

 

 

156

 

Depreciation and amortization, including film asset

   amortization

 

 

 

59,281

 

 

 

 

4,737

 

 

 

 

54,544

 

 

 

 

60,953

 

 

 

 

5,276

 

 

 

 

55,677

 

EBITDA

 

$

 

(25,357

)

 

$

 

(2,333

)

 

$

 

(23,024

)

 

$

 

113,839

 

 

$

 

19,234

 

 

$

 

94,605

 

Share-based and other non-cash compensation

 

 

 

22,518

 

 

 

 

885

 

 

 

 

21,633

 

 

 

 

22,880

 

 

 

 

573

 

 

 

 

22,307

 

(Gain) loss in fair value of investments

 

 

 

(1,087

)

 

 

 

(364

)

 

 

 

(723

)

 

 

 

2,543

 

 

 

 

807

 

 

 

 

1,736

 

Write-downs, including asset impairments and

   credit loss expense

 

 

 

32,743

 

 

 

 

8,590

 

 

 

 

24,153

 

 

 

 

5,781

 

 

 

 

2,183

 

 

 

 

3,598

 

Loss from equity accounted investments

 

 

 

1,799

 

 

 

 

 

 

 

 

1,799

 

 

 

 

41

 

 

 

 

 

 

 

 

41

 

Exit costs, restructuring charges and associated impairments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,234

 

 

 

 

 

 

 

 

4,237

 

Legal arbitration award

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,237

 

 

 

 

 

 

 

 

9,234

 

Executive transition costs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,994

 

 

 

 

 

 

 

 

2,994

 

Adjusted EBITDA per Credit Facility

 

$

 

30,616

 

 

$

 

6,778

 

 

$

 

23,838

 

 

$

 

161,549

 

 

$

 

22,797

 

 

$

 

138,752

 

Revenues attributable to common

   shareholders(2)

 

 

 

205,292

 

 

 

 

19,486

 

 

 

 

185,806

 

 

 

 

380,349

 

 

 

 

38,117

 

 

 

 

342,232

 

Adjusted EBITDA margin attributable to common

   shareholders

 

 

 

14.9

%

 

 

 

34.8

%

 

 

 

12.8

%

 

 

 

42.5

%

 

 

 

59.8

%

 

 

 

40.5

%

_____________

13


(1) Senior Secured Net Leverage Ratio calculated using twelve months ended Adjusted EBITDA per Credit Facility. During the second quarter of 2020, the Company entered into the Amendment to the Credit Facility Agreement which provides for, among other things, the suspension of the Senior Secured Net Leverage Ratio financial covenant through the first quarter of 2021.

(2)

 

 

Three months ended September 30, 2020

 

 

Three months ended September 30, 2019

 

 

12 months ended September 30, 2020

 

 

12 months ended September 30, 2019

 

Total revenues

 

 

 

 

 

 

$

 

37,256

 

 

 

 

 

 

 

$

 

86,390

 

 

 

 

 

 

 

$

 

205,292

 

 

 

 

 

 

$

 

380,349

 

Greater China revenues

 

$

 

19,346

 

 

 

 

 

 

 

$

 

26,557

 

 

 

 

 

 

 

$

 

64,489

 

 

 

 

 

 

 

$

 

121,366

 

 

 

 

 

Non-controlling interest ownership percentage(3)

 

 

 

30.11

%

 

 

 

 

 

 

 

 

30.26

%

 

 

 

 

 

 

 

 

30.22

%

 

 

 

 

 

 

 

 

31.41

%

 

 

 

 

Deduction for non-controlling interest share of revenues

 

 

 

 

 

 

 

 

(5,825

)

 

 

 

 

 

 

 

 

(8,036

)

 

 

 

 

 

 

 

 

(19,486

)

 

 

 

 

 

 

 

(38,117

)

Revenues attributable to common shareholders

 

 

 

 

 

 

$

 

31,431

 

 

 

 

 

 

 

$

 

78,354

 

 

 

 

 

 

 

$

 

185,806

 

 

 

 

 

 

$

 

342,232

 

 

(3) Weighted average ownership percentage for change in non-controlling interest share

14


IMAX CORPORATION

Adjusted Net (Loss) Income Attributable to Common Shareholders and Adjusted Diluted Per Share Calculations

(In thousands of U.S. dollars)

(Unaudited)

 

 

 

Three Months Ended

 

 

Three Months Ended

 

 

 

September 30, 2020

 

 

September 30, 2019

 

(In thousands of U.S. dollars, except per share amounts)

 

Net Loss

 

 

Diluted EPS

 

 

Net Income

 

 

Diluted EPS

 

Reported net (loss) income attributable to common shareholders

 

$

(47,209

)

 

$

(0.80

)

 

$

9,033

 

 

$

0.15

 

Adjustments(1):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

5,019

 

 

 

0.09

 

 

$

5,390

 

 

 

0.09

 

(Gain) loss in fair value of investments

 

 

(1,091

)

 

 

(0.02

)

 

 

341

 

 

 

 

COVID-19 government relief benefits

 

 

(2,084

)

 

 

(0.03

)

 

 

 

 

 

 

Tax Impact on items listed above(2)

 

 

611

 

 

 

0.01

 

 

 

(1,953

)

 

 

(0.03

)

Income tax effects related to the removal of the indefinitely reinvested assertion on the historical earnings of certain subsidiaries

 

 

129

 

 

 

 

 

 

 

 

 

 

Adjusted net (loss) income(1)

 

$

(44,625

)

 

$

(0.75

)

 

$

12,811

 

 

$

0.21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average basic shares outstanding

 

 

 

 

 

 

58,859

 

 

 

 

 

 

 

61,304

 

Weighted average diluted shares outstanding

 

 

 

 

 

 

58,859

 

 

 

 

 

 

 

61,479

 

 

 

(1)

Reflects amounts attributable to non-controlling interests.

 

(2)

The tax impact on the listed items includes a year-to-date additive adjustment in the current year related to the valuation allowance recorded in respect of certain deferred tax assets booked in the three months ended September 30, 2020.

 

 

 

Nine Months Ended

 

 

Nine Months Ended

 

 

 

September 30, 2020

 

 

September 30, 2019

 

(In thousands of U.S. dollars, except per share amounts)

 

Net Income

 

 

Diluted EPS

 

 

Net Income

 

 

Diluted EPS

 

Reported net (loss) income attributable to common shareholders

 

$

(122,530

)

 

$

(2.06

)

 

$

28,695

 

 

$

0.47

 

Adjustments(1):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

15,262

 

 

 

0.26

 

 

$

16,466

 

 

 

0.26

 

Exit costs, restructuring charges and associated impairments

 

 

 

 

 

 

 

 

850

 

 

 

0.01

 

Loss in the fair value of investments

 

 

661

 

 

 

0.01

 

 

 

1,742

 

 

 

0.03

 

COVID-19 government relief benefits

 

 

(5,235

)

 

 

(0.08

)

 

 

 

 

 

 

Tax impact on items listed above(2)

 

 

(584

)

 

 

(0.01

)

 

 

(4,437

)

 

 

(0.07

)

Income tax effects related to the removal of the indefinitely reinvested assertion on the historical earnings of certain subsidiaries

 

 

13,014

 

 

 

0.21

 

 

 

 

 

 

 

Adjusted net (loss) income(1)

 

$

(99,412

)

 

$

(1.67

)

 

$

43,316

 

 

$

0.70

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average basic shares outstanding

 

 

 

 

 

 

59,360

 

 

 

 

 

 

 

61,337

 

Weighted average diluted shares outstanding

 

 

 

 

 

 

59,360

 

 

 

 

 

 

 

61,509

 

 

 

(1)

Reflects amounts attributable to non-controlling interests.

 

(2)

The tax impact on the listed items includes a year-to-date additive adjustment in the current year related to the valuation allowance recorded in respect of certain deferred tax assets booked in the three months ended September 30, 2020.

Free Cash Flow:

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30, 2020

 

 

September 30, 2020

 

Net cash used in operating activities

 

$

 

(9,938

)

 

$

 

(30,818

)

Net cash used in investing activities

 

 

 

(1,885

)

 

 

 

(7,608

)

Free cash flow

 

$

 

(11,823

)

 

$

 

(38,426

)

 

15